76 related articles for article (PubMed ID: 10491443)
1. RESPONSE: re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Amirimani B; Walker AH; Weber BL; Rebbeck TR
J Natl Cancer Inst; 1999 Sep; 91(18):1588-90. PubMed ID: 10491443
[No Abstract] [Full Text] [Related]
2. Modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Rebbeck TR; Jaffe JM; Walker AH; Wein AJ; Malkowicz SB
J Natl Cancer Inst; 1998 Aug; 90(16):1225-9. PubMed ID: 9719084
[TBL] [Abstract][Full Text] [Related]
3. Re: modification of clinical presentation of prostate tumors by a novel genetic variant in CYP3A4.
Wojnowski L; Hustert E; Klein K; Goldammer M; Haberl M; Kirchheiner J; Koch I; Klattig J; Zanger U; Brockmöller J
J Natl Cancer Inst; 2002 Apr; 94(8):630-1; author reply 631-2. PubMed ID: 11959896
[No Abstract] [Full Text] [Related]
4. Increased transcriptional activity of the CYP3A4*1B promoter variant.
Amirimani B; Ning B; Deitz AC; Weber BL; Kadlubar FF; Rebbeck TR
Environ Mol Mutagen; 2003; 42(4):299-305. PubMed ID: 14673875
[TBL] [Abstract][Full Text] [Related]
5. CYP3A4 promoter variant is associated with prostate cancer risk in men with benign prostate hyperplasia.
Tayeb MT; Clark C; Sharp L; Haites NE; Rooney PH; Murray GI; Payne SN; McLeod HL
Oncol Rep; 2002; 9(3):653-5. PubMed ID: 11956645
[TBL] [Abstract][Full Text] [Related]
6. Expression of cytochrome P450 3A4 and its clinical significance in human prostate cancer.
Fujimura T; Takahashi S; Urano T; Kumagai J; Murata T; Takayama K; Ogushi T; Horie-Inoue K; Ouchi Y; Kitamura T; Muramatsu M; Homma Y; Inoue S
Urology; 2009 Aug; 74(2):391-7. PubMed ID: 19501880
[TBL] [Abstract][Full Text] [Related]
7. Identification of a novel polymorphic enhancer of the human CYP3A4 gene.
Matsumura K; Saito T; Takahashi Y; Ozeki T; Kiyotani K; Fujieda M; Yamazaki H; Kunitoh H; Kamataki T
Mol Pharmacol; 2004 Feb; 65(2):326-34. PubMed ID: 14742674
[TBL] [Abstract][Full Text] [Related]
8. CYP3A4, CYP3A5, and CYP3A43 genotypes and haplotypes in the etiology and severity of prostate cancer.
Zeigler-Johnson C; Friebel T; Walker AH; Wang Y; Spangler E; Panossian S; Patacsil M; Aplenc R; Wein AJ; Malkowicz SB; Rebbeck TR
Cancer Res; 2004 Nov; 64(22):8461-7. PubMed ID: 15548719
[TBL] [Abstract][Full Text] [Related]
9. Comprehensive evaluation of the association between prostate cancer and genotypes/haplotypes in CYP17A1, CYP3A4, and SRD5A2.
Loukola A; Chadha M; Penn SG; Rank D; Conti DV; Thompson D; Cicek M; Love B; Bivolarevic V; Yang Q; Jiang Y; Hanzel DK; Dains K; Paris PL; Casey G; Witte JS
Eur J Hum Genet; 2004 Apr; 12(4):321-32. PubMed ID: 14560315
[TBL] [Abstract][Full Text] [Related]
10. Interindividual differences in hepatic expression of CYP3A4: relationship to genetic polymorphism in the 5'-upstream regulatory region.
Westlind A; Löfberg L; Tindberg N; Andersson TB; Ingelman-Sundberg M
Biochem Biophys Res Commun; 1999 May; 259(1):201-5. PubMed ID: 10334940
[TBL] [Abstract][Full Text] [Related]
11. Whole-exome sequencing reveals defective CYP3A4 variants predictive of paclitaxel dose-limiting neuropathy.
Apellániz-Ruiz M; Lee MY; Sánchez-Barroso L; Gutiérrez-Gutiérrez G; Calvo I; García-Estévez L; Sereno M; García-Donás J; Castelo B; Guerra E; Leandro-García LJ; Cascón A; Johansson I; Robledo M; Ingelman-Sundberg M; Rodríguez-Antona C
Clin Cancer Res; 2015 Jan; 21(2):322-8. PubMed ID: 25398452
[TBL] [Abstract][Full Text] [Related]
12. Unique CYP3A4 genetic variant in Brazilian tuberculosis patients with/without HIV.
Jeovanio-Silva AL; Monteiro TP; El-Jaick KB; do Brasil PE; Rolla VC; de Castro L
Mol Med Rep; 2012 Jan; 5(1):153-61. PubMed ID: 21964586
[TBL] [Abstract][Full Text] [Related]
13. Potential implications of CYP3A4, CYP3A5 and MDR-1 genetic variants on the efficacy of Lopinavir/Ritonavir (LPV/r) monotherapy in HIV-1 patients.
Berno G; Zaccarelli M; Gori C; Tempestilli M; Pucci L; Antinori A; Perno CF; Pucillo LP; D'Arrigo R
J Int AIDS Soc; 2014; 17(4 Suppl 3):19589. PubMed ID: 25394094
[TBL] [Abstract][Full Text] [Related]
14. CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy.
Elens L; van Gelder T; Hesselink DA; Haufroid V; van Schaik RH
Pharmacogenomics; 2013 Jan; 14(1):47-62. PubMed ID: 23252948
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the influence of polymorphic variants CYP1A1 2B, CYP1B1 2, CYP3A4 1B, GSTM1 0, and GSTT1 0 in prostate cancer.
Rodrigues IS; Kuasne H; Losi-Guembarovski R; Fuganti PE; Gregório EP; Kishima MO; Ito K; de Freitas Rodrigues MA; de Syllos Cólus IM
Urol Oncol; 2011; 29(6):654-63. PubMed ID: 20884258
[TBL] [Abstract][Full Text] [Related]
16. Genetic diversity of CYP3A4 and CYP3A5 polymorphisms in North African populations from Morocco and Tunisia.
Novillo A; Romero-Lorca A; Gaibar M; Bahri R; Harich N; Sánchez-Cuenca D; Esteban E; Fernández-Santander A
Int J Biol Markers; 2015 Feb; 30(1):e148-51. PubMed ID: 25385241
[TBL] [Abstract][Full Text] [Related]
17. Phenotype-genotype variability in the human CYP3A locus as assessed by the probe drug quinine and analyses of variant CYP3A4 alleles.
Rodríguez-Antona C; Sayi JG; Gustafsson LL; Bertilsson L; Ingelman-Sundberg M
Biochem Biophys Res Commun; 2005 Dec; 338(1):299-305. PubMed ID: 16171783
[TBL] [Abstract][Full Text] [Related]
18. Genetic variability in CYP3A4 and CYP3A5 in primary liver, gastric and colorectal cancer patients.
Gervasini G; García-Martín E; Ladero JM; Pizarro R; Sastre J; Martínez C; García M; Diaz-Rubio M; Agúndez JA
BMC Cancer; 2007 Jul; 7():118. PubMed ID: 17605821
[TBL] [Abstract][Full Text] [Related]
19. Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study.
Elens L; Becker ML; Haufroid V; Hofman A; Visser LE; Uitterlinden AG; Stricker BCh; van Schaik RH
Pharmacogenet Genomics; 2011 Dec; 21(12):861-6. PubMed ID: 21946898
[TBL] [Abstract][Full Text] [Related]
20. Association between cytochrome CYP17A1, CYP3A4, and CYP3A43 polymorphisms and prostate cancer risk and aggressiveness in a Korean study population.
Han JH; Lee YS; Kim HJ; Lee SY; Myung SC
Asian J Androl; 2015; 17(2):285-91. PubMed ID: 25337833
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
